Last reviewed · How we verify
Drop-less surgery
Drop-less surgery, marketed by Line Kessel, is a unique surgical solution currently available in the market. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk lies in the lack of clear revenue data and key trial results, which may affect investor confidence and market adoption.
At a glance
| Generic name | Drop-less surgery |
|---|---|
| Also known as | Group c |
| Sponsor | Line Kessel |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION) (PHASE3)
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
- The Influence of Chemotherapy on Position Sense
- MIBG for Refractory Neuroblastoma and Pheochromocytoma (NA)
- The Effect of Lower Extremity Rotational Profile on Postural Control, Muscle Strength, Functional Capacity and Lower Extremity Function in Children With Generalized Joint Hypermobility
- Carotid Artery Corrected Flow Time and Inferior Vena Cava Collapsibility Index for Prediction of Hypotension After Induction of General Anesthesia in Geriatric Patients Undergoing Elective Surgery
- Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma (PHASE2)
- Effectiveness of Periocular Drug Injection in CATaract Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drop-less surgery CI brief — competitive landscape report
- Drop-less surgery updates RSS · CI watch RSS
- Line Kessel portfolio CI